1. Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma
   Ilaria Girolami et al, 2023, Journal of Personalized Medicine CrossRef
2. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
   Stefano Marletta et al, 2022, Journal of Personalized Medicine CrossRef
3. Recurrent Oropharyngeal Squamous Cell Carcinomas Maintain Anti-tumor Immunity and Multinucleation Levels Following Completion of Radiation
   Patricia Castro et al, 2023, Head and Neck Pathology CrossRef
4. Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study
   Ruey-Long Hong et al, 2024, Oral Oncology CrossRef
5. Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study
   Elena Guerini Rocco et al, 2022, Diagnostics CrossRef
6. Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors
   Dong Hyun Kim et al, 2024, Discover Oncology CrossRef
7. Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study)
   Luigi Lorini et al, 2024, Oral Oncology CrossRef
8. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy
   Gaetano Paolino et al, 2021, Pathology - Research and Practice CrossRef
9. Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
   Bruna Cerbelli et al, 2022, Histopathology CrossRef